- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
PharmaCielo Announces David Gordon as Chief Corporate Officer
Anthony Wile, CEO of PharmaCielo Ltd. (“the Company”) is pleased to announce that David Gordon has been appointed its Chief Corporate Officer (CCO) effective October 1, 2018.
Anthony Wile, CEO of PharmaCielo Ltd. (“the Company”) is pleased to announce that David Gordon has been appointed its Chief Corporate Officer (CCO) effective October 1, 2018.
As CCO, Mr. Gordon will be responsible for overseeing and managing relationships with news media, analysts, shareholders and regulators in addition to ensuring alignment in achieving corporate responsibility and development objectives across international operations.
David Gordon appointed Chief Corporate Officer of PharmaCielo (CNW Group/PharmaCielo)
“David has been an essential advisor to PharmaCielo since the earliest days of its establishment, guiding us on effective communication and corporate development strategies,” said Anthony Wile. “As we build out our global infrastructure, I am delighted that he has agreed to bring his impressive track record and range of experience to the table on a permanent basis to help us to continue the growth and expansion of PharmaCielo throughout both the Colombian and international marketplace.”
Previously Mr. Gordon was a principal advisor to PharmaCielo as Managing Partner of Cohn & Wolfe | Canada, one of Canada’s leading communication strategy firms, and since 2013 has served as Chair of the Canadian Council of PR Firms. Mr. Gordon was appointed to the Board of Directors of PharmaCielo Ltd. in 2016 and is a member of the Institute of Corporate Directors (ICD).
“Working with PharmaCielo and the executive team for the past several years has been an exciting period. The emergence of a new industry that challenges convention on multiple levels including international trade, public policy and communication, to name but a few, encapsulates the various fields of challenge I have experienced throughout my career,” said David Gordon. “I look forward to continuing to work with my colleagues in Canada and Colombia to help expand to the global market the leadership that PharmaCielo has demonstrated in the Colombian marketplace.”
With 20-plus years of experience in corporate strategy and brand communications, combined with a background in public policy and political strategy following a career start in international trade and combined with an MA and MBA, David Gordon is a strong believer in being an engaged member of the community and has served on the boards of a number of non-profit organizations.
About PharmaCielo
PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.
For further information:
For further information: Media Relations: David Gordon, Tel: +1 647 259 3258, d.gordon@pharmacielo.ca; (Colombia) Juan Manuel Cuellar, Tel: +57 310 3298776, Juan.M.Cuellar@Sprgroup.biz
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.